Inhibrx, Inc. (NASDAQ:INBX) Short Interest Update

by · The Markets Daily

Inhibrx, Inc. (NASDAQ:INBX – Get Free Report) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 1,200,000 shares, a growth of 10.1% from the November 30th total of 1,090,000 shares. Based on an average trading volume of 77,600 shares, the short-interest ratio is presently 15.5 days. Currently, 12.1% of the shares of the company are short sold.

Inhibrx Trading Up 1.7 %

NASDAQ:INBX opened at $15.40 on Wednesday. Inhibrx has a fifty-two week low of $10.80 and a fifty-two week high of $18.95. The stock has a fifty day moving average price of $15.11 and a 200-day moving average price of $14.64.

Insider Activity at Inhibrx

In related news, Director Jon Faiz Kayyem purchased 69,686 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was acquired at an average cost of $14.23 per share, for a total transaction of $991,631.78. Following the completion of the purchase, the director now owns 51,093 shares in the company, valued at approximately $727,053.39. This represents a -374.80 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 22.20% of the stock is currently owned by corporate insiders.

Inhibrx Company Profile

(Get Free Report)

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.

See Also